

Notice of Allowability

Application No.

10/797,545

Examiner

Bernard Dentz

Applicant(s)

REPKE ET AL.

Art Unit

1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to Amdt. of 4-18-2005.
2. ☒ The allowed claim(s) is/are 1,5-13,16-22,25-27,30-40 and 43.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 9-22-2004
4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____.

HC

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Hall on 4-18-2005.

The application has been amended as follows:

The following non-elected material has been canceled without prejudice.

Claims 4, 14, 15, 23, 24,28, 29 and 42 have been canceled.

Claim 38, line 21 which begins with "4" and ends with "oxazin-3-one" has been canceled in its entirety.

Claims 5 and 6, line 1 of each "3" has been changed to - -1- -.

Claim 16, line 1 "14" has been changed to - -6- -.

Claim 26, line 1 "25" has been changed to - -7- -.

Claim 43, line 1 "or benzoxazinone" has been canceled.

The following is an examiner's statement of reasons for allowance: Applicants have overcome the 35 USC 112 rejection by their amendments and arguments They have overcome the enablement rejection with the citing of references showing the utility of compounds which are 5-HT6 modulators. The references cited by applicants are made of record.

WO 99/50263 earlier cited by applicants discloses a genus of thrombin inhibitors including 1-(piperazin-1-ylmethylphenyl)quinol-2-ones and the corresponding 3,4-

dihydroquinol-3-ones. See page 6, line 17 to p. 12, line 16. Note the two piperazino values for Y at p. 8, lines 23 and 24. Note however that the compounds must contain a cyclic substituent at the 3-position. See the values of said substituent, i.e. R7, at p.8, line 29 to p. 9, line 34. Note that all of the disclosed species (p. 18 to p.39) have this substituent. Note also that the disclosed synthetic methods all prepare compounds containing this 3-position substituent. See p. 46, line 15 to p.60, line 20. Thus the instant compounds which are unsubstituted (preferred) or alkyl substituted at the 3-position are not anticipated and are also unobvious over this reference.


Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bernard Dentz whose telephone number is 571-272-0683. The examiner can normally be reached on Mon.-Fri. 8AM-4:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on 571-272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Dentz
4-18-2005

A handwritten signature in black ink, appearing to read "B. Dentz", with a date "4-18-2005" written below it.